Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
Dyne Therapeutics(US:DYN) The Motley Fool·2025-12-09 11:00A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.On November 14, Austin-based Saturn V Capital Management disclosed a buy of Dyne Therapeutics (DYN +9.47%), increasing its position by 1.2 million shares and an estimated $20 million based on quarterly average pricing.What HappenedAccording to a SEC filing for the period ended September 30, Saturn V Capital Management LP increased its stake in Dyne Therapeutics by abou ...